Lavita AI, a pioneering AI+Web3 healthcare platform, has successfully raised $5 million in a seed financing round led by Camford Capital, along with participation from angel investors from the blockchain and AI industries. The funds obtained will be utilized to expedite the development of Lavita’s AI-first platform and applications, catering to patients, healthcare providers, and research institutions.
Lavita envisions revolutionizing the global management, sharing, and utilization of health data, thereby enhancing access to healthcare services and improving patients’ lives. The platform, built on decentralized principles, offers a privacy-preserving infrastructure to securely share and analyze health data, restoring ownership, control, and value of health data to individuals.
Lavita’s platform will facilitate a wide range of applications in life science research, biopharmaceutical development, and healthcare innovation. For instance, individuals can leverage the platform to dynamically identify and match with ongoing clinical trials worldwide, including those that historically face challenges in recruitment, such as pivotal clinical studies or trials for rare diseases.
Life science researchers can convene data cohorts for large-scale population studies like genome-wide and phenome-wide association studies. Biopharmaceutical companies can securely share data across multiple entities for applications in drug discovery and development partnerships. Health institutions will have the opportunity to collaborate on the Lavita platform to train and fine-tune their own large language models (LLMs) for domain-specific use cases such as medical imaging and clinical records.
Ali Farahanchi, co-founder and head of business and operations at Lavita AI, expressed enthusiasm about the financing round and the integration with Theta, a leading provider of Web3 infrastructure. The collaboration will expedite the launch of the first decentralized peer-to-peer marketplace for health data. Health data owners, including patients, health networks, and research centers, will be able to securely share data while maintaining control and privacy, thus accelerating the development of new treatments.
The partnership between Lavita and Theta Network will enable individuals to participate in the platform and earn LAVITA tokens, a new set of TNT-20 tokens built on the Theta Metachain. These tokens can be utilized to access services from participating healthcare institutions and to engage in the Theta Edge Network, a decentralized Web3 infrastructure that provides distributed computation and storage for training and fine-tuning healthcare AI models.
Mitchell Liu, co-founder and CEO of Theta Labs, emphasized Lavita AI’s pioneering role in enabling patients to own their digital health assets and information, granting control and monetization without relying on third-party data brokers. One of Lavita’s initial applications will be clinical trial matching, built on a custom Theta subchain, allowing multiple stakeholders to access and share sensitive health information securely.
Patients will have the ability to upload their health data, be rewarded in LAVITA TNT-20 tokens, and directly access clinical trial options without solely relying on physicians for information.
Lavita AI was recently selected for the Microsoft for Startups Founders Hub Program, further highlighting its growing recognition and support in the industry. To learn more about Lavita AI, interested parties can download the white paper to gain comprehensive insights into the platform’s capabilities and vision.
